Key result
In pediatric cardiac intensive care patients, the tinzaparin dose required to achieve target anti-Xa levels was significantly higher than the recommended starting dose (+51 U/kg; p=0.003).
Why the study?
Does standard tinzaparin dosing achieve target anti-Xa levels in pediatric cardiac intensive care patients?
Population
39 children admitted to a single tertiary-level PICU, median age 13 months, with 46 episodes of newly…
Design
Cohort
Authors
Loading...
Subtherapeutic anti-Xa levels predominate with standard tinzaparin dosing in PICU children; hypothesis-generating for higher requirements, needs prospective trials before practice change.
Observational (n=39)
No
Does standard tinzaparin dosing achieve target anti-Xa levels in pediatric cardiac intensive care patients?
Mean Difference: 51
p-value: p=0.003
Pediatric cardiac intensive care patients require significantly higher tinzaparin doses than currently recommended to achieve therapeutic anti-Xa levels.
Roeleveld et al. (2016) conducted an observational in Pediatric cardiac intensive care patients requiring anticoagulation (n=39). Tinzaparin vs. Recommended starting dose was evaluated on Dose required to achieve target anti-Xa levels (0.5-1.0 IU/mL) (MD 51 U/kg, p=0.003). In pediatric cardiac intensive care patients, the tinzaparin dose required to achieve target anti-Xa levels was significantly higher than the recommended starting dose (+51 U/kg; p=0.003).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: